GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SK Biopharmaceuticals Co 326030.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

86,700

-2.36%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩706.74bn

FY2016FY2025

Net income

₩266.95bn

FY2016FY2025

Free cash flow

₩146.82bn

FY2016FY2025

Shareholders' equity

₩813.04bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩706.74bn₩547.60bn₩354.89bn₩246.18bn₩418.64bn₩26.00bn₩123.85bn₩1.10bn₩85.32bn₩89.93bn
Research and development₩174.34bn₩161.27bn₩137.13bn₩122.82bn₩114.53bn₩108.44bn₩176.21bn₩121.29bn₩85.60bn₩53.54bn
Operating income₩203.94bn₩96.34bn−₩37.52bn−₩131.08bn₩94.96bn−₩237.57bn−₩79.26bn−₩139.10bn−₩97.97bn−₩57.67bn
Net income₩266.95bn₩240.74bn−₩32.88bn−₩139.43bn₩64.85bn−₩247.41bn−₩71.52bn−₩138.10bn−₩97.65bn−₩30.36bn
Diluted earnings per share3,408.753,074.04-419.89-1,780.43828.03-3,159.28-845.60-1,632.76-1,154.54—

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩1.20trn₩1.04trn₩723.17bn₩664.24bn₩643.65bn₩500.24bn₩139.07bn₩95.54bn₩98.37bn₩193.89bn
Total liabilities₩372.04bn₩462.83bn₩402.22bn₩347.68bn₩199.46bn₩121.17bn₩152.10bn₩36.91bn₩51.12bn₩46.21bn
Debt—₩184.48bn₩178.05bn₩155.90bn₩15.74bn₩18.48bn₩109.06bn———
Shareholders' equity₩813.04bn₩546.27bn₩283.69bn₩316.56bn₩444.19bn₩379.07bn−₩13.03bn₩58.63bn₩47.24bn₩147.69bn
Shares outstanding78m78m78m78m78m78m85m85m85m—

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩176.33bn₩94.90bn−₩94.20bn−₩159.92bn−₩92.87bn−₩210.73bn−₩81.33bn−₩141.28bn−₩98.34bn−₩48.94bn
Capital spending−₩29.51bn−₩13.42bn−₩3.25bn−₩4.91bn−₩4.32bn−₩11.02bn−₩14.05bn−₩1.44bn−₩1.65bn−₩8.80bn
Free cash flow₩146.82bn₩81.48bn−₩97.45bn−₩164.83bn−₩97.19bn−₩221.75bn−₩95.38bn−₩142.72bn−₩99.99bn−₩57.74bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩247.37bn₩227.89bn₩194.36bn₩191.73bn₩176.28bn₩144.38bn₩163.02bn₩136.60bn
Operating income₩97.06bn₩89.77bn₩46.28bn₩70.11bn₩61.88bn₩25.67bn₩40.65bn₩9.64bn
Net income₩85.06bn₩105.16bn₩136.59bn₩74.14bn₩32.92bn₩23.30bn₩190.12bn₩9.65bn
Diluted earnings per share1,086.211,342.841,744.19946.67420.32297.582,427.63123.28
Cash from operations₩78.15bn₩17.92bn₩87.00bn₩65.41bn−₩3.37bn₩27.29bn₩56.85bn₩22.46bn
Capital spending−₩909.0m−₩2.94bn−₩26.55bn−₩1.28bn−₩1.21bn−₩477.0m−₩601.0m−₩12.12bn
Free cash flow₩77.24bn₩14.97bn₩60.46bn₩64.13bn−₩4.57bn₩26.81bn₩56.25bn₩10.33bn
Total assets₩1.42trn₩1.32trn₩1.20trn₩1.03trn₩952.82bn₩1.00trn₩1.04trn₩775.02bn
Shareholders' equity₩1.02trn₩932.05bn₩813.04bn₩672.80bn₩595.24bn₩567.53bn₩546.27bn₩337.91bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue42.1%93.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings36.536.1-239.1-40.5117.4-53.5
Price to sales13.815.922.222.918.2—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.